Randomized Trialhigh evidence
Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial.
Journal of the American Academy of Dermatology·May 14, 2026·PMID 42140362
Why it mattersTransgender patients on testosterone often develop androgenetic alopecia, yet standard treatments like 5α-reductase inhibitors may interfere with masculinization. Sublingual minoxidil offers a safe, effective alternative that does not alter testosterone concentrations, addressing a key clinical concern in this population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled